Abstract
To determine the effects of neoadjuvant chemotherapy (NAC) in the management of cervical carcinoma Stage IB2 (tumor diameter > 4 cm), we reviewed 52 surgically treated patients diagnosed between January 1987 and December 1993. There were 20 patients treated with preoperative neoadjuvant chemotherapy and 32 treated by primary radical hysterectomy. Mean tumor diameter was significantly larger in the neoadjuvant, compared with the primary surgery group (6.5 +/- 1.8 vs 5.4 +/- 0.7, P = 0.003). In the NAC group, 5 of 20 patients were treated with three courses of cisplatin, methotrexate, and bleomycin every 21 days, whereas 15 of 20 patients received three courses of cisplatin, vincristine, and bleomycin every 10 days. Postoperative adjuvant therapy consisting of either radiation or chemotherapy was employed in 13/20 patients (65%) in the NAC group and 20/32 patients (63%) in the primary surgical group. At a median follow-up of 52.5 months, 4/20 patients (20%) in the NAC group recurred vs 11/32 (34%) in the primary surgery group. The overall response rate to NAC was 90%, with 2/20 complete clinical responders and 16/20 partial responders. High-risk pathologic factors were less commonly observed in the NAC group when compared with th...Continue Reading
References
Jun 1, 1992·Cancer·C A PerezM A Lockett
Jan 11, 1992·International Journal of Radiation Oncology, Biology, Physics·W W ThomsM J Oswald
Sep 1, 1990·Gynecologic Oncology·J SardiG di Paola
Jan 15, 1991·Cancer·P B PaniciC Rabitti
Jan 1, 1991·Gynecologic Oncology·P R DottinoC J Cohen
Nov 1, 1991·Gynecologic Oncology·R D AlvarezH M Shingleton
Apr 1, 1990·Gynecologic Oncology·M E PotterK D Hatch
Jul 15, 1990·Cancer·E PodczaskiR Mortel
Aug 1, 1990·Gynecologic Oncology·J C RemyM Rotman
Jul 1, 1989·Gynecologic Oncology·J L LovecchioJ Bell
Nov 1, 1989·Gynecologic Oncology·R D AlvarezH M Shingleton
Jul 15, 1985·Cancer·H H GallionJ Yoneda
Sep 1, 1984·Gynecologic Oncology·M L FriedlanderM H Tattersall
May 1, 1993·Gynecologic Oncology·J SardiC Vico
Jun 1, 1995·Gynecologic Oncology·G L EddyW T Creasman
Feb 15, 1993·Cancer·W B Jones
Nov 15, 1995·Cancer·H M ShingletonR E Clive
Aug 1, 1996·Gynecologic Oncology·M A FinanD Cavanagh
Citations
Oct 14, 2008·BMC Cancer·Chel Hun ChoiDuk-Soo Bae
Jul 5, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·C Lopez-GranielA Dueñas-Gonzalez
Nov 17, 2001·American Journal of Clinical Pathology·S CostaK Syrjänen
May 25, 2010·The Journal of Obstetrics and Gynaecology Research·Chel Hun ChoiDuk-Soo Bae
Sep 21, 2005·Gynecologic Oncology·Yaeko KobayashiKatuhiko Hasumi
Mar 18, 1999·Hematology/oncology Clinics of North America·K GrevenR Lanciano
Jan 2, 2003·Obstetrics and Gynecology Clinics of North America·David O Holtz, Charles Dunton
May 3, 2005·Gynecologic Oncology·Rodney P RocconiJ Michael Straughn
May 3, 2005·Gynecologic Oncology·W TermrungruanglertN Sirisabya
Aug 15, 2006·Gynecologic Oncology·Chel Hun ChoiDuk-Soo Bae
Jun 5, 2003·Expert Opinion on Pharmacotherapy·David H Moore
May 18, 1999·Gynecologic Oncology·R J ChenC Y Hsieh
Jan 4, 2001·Gynecologic Oncology·S CostaK Syrjänen
Oct 26, 2000·The Journal of Obstetrics and Gynaecology Research·S J Kim
Jun 26, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·T MoriH Honjo
Aug 19, 2006·Anti-cancer Drugs·Munetaka TakekumaIchiro Ito
Feb 2, 2002·Current Oncology Reports·David H Moore
Mar 5, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Kyung-Do KiSeon-Kyung Lee
Nov 16, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Roberto AngioliPierluigi Benedetti-Panici
Nov 15, 2001·Anti-cancer Drugs·H TsudaK Yamamoto
Sep 2, 2020·The Journal of International Medical Research·Shu-Li YangYu-Mei Wu
Dec 1, 2020·Frontiers in Oncology·Bingxin ChenHui Wang